ABCA1 protein releases molecular brakes on solid tumor immunotherapy, study finds

In recent years, cancer researchers have made major breakthroughs by using the body's immune system to fight cancer. One of the most promising approaches, known as immune checkpoint blockade, works by releasing molecular "brakes" on T cells. This allows them to better recognize and attack cancer cells. While these therapies can be very effective for some patients, many solid tumors, including most forms of breast cancer, remain largely unaffected. Cancer Center at Illinois (CCIL) Program Co-leader Erik Nelson and his research group are working to understand why these treatments fail.